IDEXX LABORATORIES INC /DE News
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
see moreIDEXX LABORATORIES INC /DE Market News
10d
IDEXX Laboratories Sees Institutional Portfolio Shifts as Director Files for Stock Sale
- In the past week, IDEXX Laboratories (NASDAQ:IDXX) drew attention from investors as a director filed to sell shares and institutions adjusted their holdings—moves with potential implications for stock dynamics.
24d
IDEXX Laboratories Unveils Dual-Species NT‑proBNP Test, Enhancing Catalyst Platform
IDEXX Laboratories has expanded its Catalyst diagnostics with a first‑ever dual‑species point‑of‑care NT‑proBNP test, offering enhanced cardiac disease detection.
12 Aug at 15:18
IDEXX Laboratories' Stock Declines Amidst Industry Innovations and Market Dynamics
IDEXX Laboratories' stock faces decline amid industry innovations and market shifts.
31 Jul at 13:18
IDEXX Laboratories Faces Stock Volatility Despite Positive Q1 Earnings and Innovations
IDEXX Laboratories' stock performance has experienced notable fluctuations recently, driven by a mix of analyst ratings and strong earnings reports in veterinary diagnostics.
26 Jul at 19:24
IDEXX Laboratories' Stock Performance Amidst Recent Developments in Veterinary Diagnostics
Analyzing IDEXX's stock trends in light of recent industry advancements.